Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02502188Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CC-90005 in plaque psoriasis (2 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs) up to 12 months. Started Jul 2015; status: terminated.
02
Drugs
CC-90005
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02502188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502188.